Macrophages play a key role in the inflammatory reaction of body defense. It has been demonstrated that there are various types of macrophages and their function greatly affects the progressive conditions of inflammation process. The objective of this study is to develop a drug delivery system (DDS) which can modify the biological function of macrophages. Pioglitazone (Pio) of waterinsolubility was water-solubilized by the micelle formation with gelatin grafted with L-lactic acid oligomer (Pio-micelles). The Pio water-solubilized was incorporated into a biodegradable gelatin hydrogel. The experiments of Pio release and hydrogel degradation revealed that pio was released from the hydrogel incorporating Pio-micelles in vitro and in vivo. The Pio-micelles and Pio allowed macrophages to enhance the mRNA expression level of arginase1 which is a measurement of type 2 macrophages. When applied to a skin defect model of mice, the hydrogels incorporating Pio-micelles enhanced the arginase1 level around the site implanted to a significant great extent compared with the Pio solution. The Pio release technique is promising to modify the phenotype of macrophages.
Introduction
Macrophages have remarkable plasticity in physiology and change their phenotype in response to the environmental cues, resulting in the generation of various populations with different biological functions. It has been recognized that there are, at least, two phenotypes of macrophages, called as M1 and M2. M1 macrophages with classically proinflammatory functions are typical in inflammatory reactions and pathogen defense [1] [2] [3] . Generally, M1 macro- helper T cells associated with tumor progression 2) , parasite infections, tissue repair 3, 4) , and debris removal [4] [5] [6] [7] . The M2 macrophages produce IL-10, high levels of scavenger, mannose, and galactose receptor, and arginase in the place of arginine 4) , subsequently producing ornithine and polyamines.
The concepts and paradigms of macrophages polarization into M1 and M2 phenotypes have been noted in terms of inflammatory host responses to pathogens and cancer 3, 4, 8) .
The macrophages phenotype also modify the host response in disease pathogenesis, tissue injury, and the implantation of biomaterials 9) . The findings give us the idea that the inflammatory host responses can be modified by changing the macrophages phenotype.
Peroxisome proliferator-activated receptor γ (PPARγ)
is one of the key factors to modify the M1/M2 phenotype ratio [10] [11] [12] . It is demonstrated that the activation of PPARγ potentiates the polarization of circulating monocytes to macrophages of M2 type, and reduces the functions of M1 macrophages and attenuates macrophages-induced inflammatory reactions 13) . Among the activators of PPARγ pioglitazone of a thiazolidinedione (TZDs) is commercially available, and well-known as an agonist for PPARγ and modulator of inflammatory responses 14) .
Gelatin is a biodegradable material and has been extensively used for food, pharmaceutical, and medical purposes.
The biosafety has been proven through their long practical applications. Biodegradable hydrogels prepared from gelatin were effective as the release carrier of watersoluble [15] [16] [17] [18] and water-insoluble drugs 19) and augmented their therapeutic activities. 
3)Synthesis of gelatin grafted with LAo
Gelatin grafted with LAo was synthesized as reported previously 19) . Briefly, 1.0 g of PI5 gelatin with Mw of 5,000, 10,000, 20,000, 60,000 and 100,000 was dissolved in anhydrous dimethyl sulfoxide (DMSO) at room temperature.
DSC and DMAP were added to the LAo solution in DMSO at the molar ratio to LAo of 3, followed by stirring at room temperature for 3 hr to activate the hydroxyl groups of LAo.
Next, the mixed solution was slowly added to the gelatin solution in DMSO to give the LAo/gelatin molar ratios of 1, 3, 5, and 7, and then stirred overnight at room temperature to allow LAo to graft to gelatin. The resulting solution was dialyzed with dialysis tube against double-distilled water (DDW) for 72 hr at room temperature, and freeze-dried to obtain LAo-grafted gelatin samples (LAo-g-gelatin).
4)Water-solubilization of Pio by LAo-g-gelatin
Pio solution (1.0 mg/ml) in DMSO (15 ml) was added to 30 ml of LAo-grafted gelatin DMSO solution (1.0 mg/ml), followed by 3 hr stirring at room temperature. Then, the mixed solution was dialyzed with Spectra/Por ® Dialysis
Membrane MWCO: 3,500 (Spectrum Laboratories, Inc, CA, US) against DDW for 72 hr at room temperature. The dialysate obtained was centrifuged (8,000 rpm, 10 min, 25 ℃) to exclude the water-insoluble fraction, and freeze-dried to obtain the Pio water-solubilized by LAo-grafted gelatin micelles (Pio-micelles). The amount of Pio was measured on high performance liquid chromatography (HPLC, HPLC prominence LC-20AT, Shimadzu, Japan). The Piomicelles were dissolved by ethanol, followed by the HPLC measurement to assess the Pio amount by referring the calibration curve of Pio amount and HPLC peak area.
5)Activity evaluation of Pio-micelles
To evaluate the biological activity of Pio-micelles, the conventional bioassay of in vitro cell culture was carried out 10, 12, 13) . Briefly, bone marrow-derived macrophages (PBS, pH 7.4) two times, followed by lysing in RLT buffer (Qiagen Inc., Osaka, Japan), and then the cell RNA was isolated using an RNeasy Mini Kit (Qiagen Inc., Osaka, Japan) according to the instructions of manufacturer. Total RNA was reverse transcribed using superscript VILO cDNA synthesis kit (InvitrogenTM , CA.).
6)Preparation of gelatin hydrogels incorporating Piomicelles
The gelatin hydrogel incorporating Pio-micelles were prepared through the dehydrothermal crosslinking reaction of gelatin 20) . Briefly, Pio-micelles (10 mg/ml) were added to 10 wt% of PI9 gelatin aqueous solution. Then, the solution was mixed, cast into a mold (2 cm x 2 cm) and freezedried. The samples freeze-dried were dehydrothermally crosslinked at 160 ℃ for 24 hr to obtain hydrogels incorporating Piomicelles (Pio-hydrogels). 
7)In

9)In vivo evaluation of Pio bioactivity
Pio-hydrogels or Pio-free hydrogels were implanted as 
11)Gene expression assay
Mice were sacrificed 7 days after treatment, and the tissue including the skin wound (1 cm x 1 cm) was taken minced, and digested in the PBS containing collagenase D (2 mg/ml). After 1 hr incubation at the 37 ℃, tissue digested was treated similarly to obtain the single cell suspension.
A CD11b + cell fraction was then sorted using Dynabeads
Biotin Binder (Invitrogen TM , CA.), according to the manufacturer's protocol. Briefly, the cells in the suspension were labeled with a biotin-conjugated rat anti-mouse CD11b 
12) Statistical analysis
All the data were statistically analyzed by using TukeyKramer tests for multiple comparisons, and the statistical significance was indicated by a p value less than 0.05. The experimental results were expressed as the mean ± the standard deviation.
Results
1)Water-solubilization of Pio by LAo-g-gelatin and
bioactivity Figure 1 shows the percentage of Pio water-solubilized by various LAo-g-gelatin samples. Irrespective of the LAo grafted ratio, Pio was solubilized in water by mixing with the LAo-g-gelatin. However, the percentage decreased with an increase in the ratio of LAo grafted. Figure 2 shows the mRNA level of iNOS and Arginase1 for BMM cultured with free Pio and Pio-micelles. Similarly to free Pio, the Pio-micelles significantly suppressed the iNOS expression by a factor of 2 ( Fig. 2A) . The Pio-micelles and free Pio significantly, enhanced the arginase 1 expression.
2)In vitro bioactivity of Pio-micelles
And the enhancement by the Pio-micelles was significantly high compared with that by free Pio. Figure 3A shows the time profile of Pio release from Piohydrogels. Pio release from the time Pio-hydrogels was hardly observed in PBS. However, Pio was released with time in the presence of collagenase. The time profile of Pio release was in a good accordance with that of hydrogel degradation (Fig. 3B) . Figure 4 shows the in vivo time profiles of Pio release from Pio-hydrogels. The Pio was released from the Piohydrogels in vivo. Figure 5 shows the time course of arginase1 gene expression on the CD11b + cells of tissues around Pio-hydrogels implanted. There is no significance difference in the level between the Pio-hydrogels and Pio-free hydrogels 1 and 3 days after implantation. However, significant higher expression of arginase1 was observed for the Pio-hydrogels 7 days later. incoporration were degraded 7 days after implantation. Figure 7 shows the time course of wound skin defect size 0 and 7 days after treated with saline (cont), Pio-micelles, Pio-free hydrogels, and Pio-hydrogels. A wound closure was observed for the skin defects treated with saline and free Pio-micelles, but no epithelialization was seen. For the Pio-free hydrogels group, neither around closure nor epithelialization were observed. On the contrary, the Piohydrogels accelerated the wound closure accompanied with epithelialization. Figure 8 shows percent wound area and epithlialization at the skin defect of mice 7 days after treatment with saline, Pio-micelles, Pio-free hydrogels, and Pio-hydrogels. The percent wound area was significantly suppressed by the Pio-hydrogels and Piomicelles, in contrast with Pio-free hydrogels. On the other hand, the Pio-hydrogels significantly enhanced the percent epithelialization of skin defects. Figure 9 shows the arginase1 gene expression of CD11b + cells in the tissue treated with pio-hydrogels and others.
3)Pio release profiles of Pio-hydrogels
4)In vivo biological activity of Pio-hydrogel
The gene level for the Pio-hydrogels group was significant higher than that of Pio-micelles, Pio-free hydrogels, and control groups.
Discussion
The present study demonstrates that Pio released from the gelatin hydrogels modified the profile of gene expression for macrophages in vitro and in vivo . The
Pio of a water-insoluble drug was solubilized in water by making use of LAo-g-gelatin micelles. Then, the Pio watersolubilized (Pio-micelles) was crosslinked with gelatin to prepare the gelatin hydrogel incorporating Pio-micelles (Pio-hydrogels). No Pio release was observed from the Pio-Original Article Controlled release of pioglitazone to modify Mφ phenotype hydrogels in PBS where the hydrogels are not degraded (Fig. 3A) . Gelatin is normally degraded by enzymes, but not by a simple hydrolysis. In the presence of collagenase, it is likely that the hydrogels are degraded enzymatically to generate gelatin water-soluble fragments, resulting in the hydrogel degradation-based Pio release. There was a good correlation in the time profile between the Pio release and the hydrogel degradation (Fig. 3B) . This strongly indicates that the Pio release is governed only by the degradation of hydrogels as the release carrier. The in vivo Pio release was observed (Fig. 4) .
In this study, we focused on macrophages which play a key role in the regulation of inflammation process, and tried to artificially modify their functional phenotype by a drug. To enhance the drug activity, the controlled release was tried. However, for that purpose, the material of drug release carrier should be biodegraded and biocompatible, because the material remaining often causes inflammation.
Many biodegradable materials have been investigated
as the carrier of drug release [15] [16] [17] [18] [19] [20] [21] . However, most of them remain even after the role of drug release completes, and consequently the remaining often induces inflammation responses to the material. As one trial to tackle this problem, the material of drug carrier used must be degraded to disappear accompanied with the drug release in a synchronized manner. From this point, the gelatin hydrogel is advantageous over other release materials. The drug is release from the gelatin hydrogel as a result of hydrogel degradation 22) . When the drug release completes, the hydrogel disappears, which does not cause the materialinduced inflammation.
To induce the phenotype modification of macrophages,
we used the pioglitazone of a PPARγ agonist which has an ability to change the macrophages function. It is demonstrated that the activation of PPARγ signaling plays a protective role in the tissue remodeling and wound repair by reducing oxidative stress and inflammation 23) . The local administration of rosiglitazone of another PPARγ agonist induced antiinflammatory responses 24) and increased the expression of M2-specific marker 25) . Among the PPARγ agonists, Pio is commercially available and one of the strong modulators for PPARγ. It has been clinically used as a diabetic's drug. Based on that, Pio is a good candidate to experimentally confirm the function to modify the macrophages M1/M2 ratio aiming at the clinical application. As expected, this study demonstrates that this agonist enabled macrophages to modify the cell phenotype.
To evaluate the effect of Pio on the macrophages phenotype, BMM were cultured with Pio-micelles to evaluate the level of iNOS and arginase1 mRNA expression.
The iNOS and arginase1 are known as a M1 and M2 markers, respectively. Generally, M1-type macrophages exhibit an increased NOS activity which promotes the L-hydroxyarginine, L-citrulline, and NO production contributing to the anti-microbial activity 26) . On the contrary, for M2-type macrophages, the arginase1 activity increases while the NOS activity decreases 27) . L-arginine is converted by arginase1 to Lornithine of an important substance to produce polyamines for cell proliferation, or proline of a collagen building block, to promote tissue repair 28) . When the BMM were cultured with free Pio and Pio-micelles, the level of iNOS expression significantly decreased. On the contrary, the arginase1 expression level increased significantly (Fig. 2) . Some researches have demonstrated that the activation of PPARγ inhibited the expression of pro-inflammatory genes including cytokines and iNOS 29, 30) .
The arginase1 expression is regulated by PPARγ . These results reported are similar to the findings of this study. The
Pio-micelles have a potential to allow BMM to enhance the arginase1 activity of M2 macrophages measure.
When the Pio-hydrogels were subcutaneously implanted into the mouse skin, the arginase1 expression level of CD11b + cells increased 7 days after implantation, to a significantly great extent compared with that of Piofree hydrogels (Fig. 5) . Pio was released in vivo (Fig. 4) .
We can say with certainty that Pio released from Piohydrogels could modify the CD11b + cells of macrophage to
show the M2 phenotype even in vivo. The similar trend of macrophages phenotype modification was observed for the skin wound model of mice. A significantly higher arginase1 expression was detected for CD11b + cells in the tissue around the wound after the implantation of Pio-hydrogels than for the same dose of free Pio and Pio-free hydrogels (Fig. 9) . It is possible that the controlled release of Pio enabled macrophages to make the phenotype M2-type more efficiently compared with the injection of free Pio. The
Pio local release would increase the possibility of Pio action to macrophages, resulting in an enhanced Pio-induced phenotype change.
The wound area was significantly reduced by the application of Pio-hydrogels (Fig. 7) . The Pio-hydrogels accelerated the wound closure accompanied with epithelization (Fig. 8) . Free Pio-micelles promoted the wound closure, although the extent was significantly small co-cultures 4, 32, 33) . Macrophages phenotype can also be altered by the phagocytosis of apoptotic or necrotic cells [34] [35] [36] . Wound-healing or tissue repair functions are physiologically modified by macrophages of an M2a or M2 phenotype 3, 37, 38) . Macrophages during the process of skin wound healing exhibit a heterogeneous and temporally regulated phenotype that does always classify into M1/M2 categorization 39) . The macrophages phenotype related to the skin wound healing is determined by the microenvironment more complex than treatment with one or a few cytokines in a cellculture system. Therefore, it is not surprising that the phenotype of in vivo tissue repairing macrophages do not always correspond to that of in vitro defined categories.
We cannot observe significant different in the gene ex- . TZDs were found to be effective in treating type 2 diabetes as they directly reduced the systemic insulin resistance of peripheral tissues 41, 42) . A potential therapeutic action of PPARγ agonists improves the strongly impaired angiogenic process in diabetic wound tissue 43) . We revealed that the diabetic wound healing was accelerated by Pio-hydrogels, in contrast to free Piomicelles and Pio-free hydrogels (data not shown). PPARγ is a member of the nuclear receptor family that includes 48
human transcription factors whose activity is regulated by direct binding of steroid and thyroid hormones, vitamins, lipid metabolites and xenobiotics 44) .
It is demonstrated that
TZDs function by the activation of nuclear hormone receptor 45) . The PPAR family of transcription factors consists of two additional members: PPARα and PPARβ/δ, and all members heterodimerize with 9-cis-retinotic acid retinoid X receptors 46, 47) . Epidermal keratinocytes express all three PPAR subtypes 48) . Keratinocytes are well known produce vascular endothelial growth factor (VEGF) at the wound site 5) and in vitro 49) . Angiogenesis is induced by the VEGF production which is one of the keys contributing to the skin repair 50, 51) . Therefore, it is possible that the mechanism of in vivo wound healing is not only due to the change in macrophages phenotype, but also to the function of PPARγ.
PPARγ
Considering the present data and these reported previously, it is highly conceivable that the local release of Pio induces the production of various factors and angiogenesis in addition to the modification of macrophages phenotype, resulting in an enhanced wound healing.
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